EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preclinical Metabolism and Disposition of TP0473292, a Novel Oral Prodrug of the Potent Metabotropic Glutamate 2/3 Receptor Antagonist TP0178894 for the Treatment of Depression

Shoko Inatani iD, Motoki Ochi, Kohnosuke Kinoshita iD, Jun-Ichi Yamaguchi, Hiromi Endo

Drug Metabolism and Disposition · 2023

DOI: 10.1124/dmd.122.001116 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2023. Verfasst von Shoko Inatani und 4 weiteren Autor:innen. Beteiligte Einrichtung: Drug Metabolism and Pharmacokinetics, Drug Safety and Pharmacokinetics Laboratories, Research Headquarters, Taisho Pharmaceutical Co., Ltd., Saitama,…. Hauptthemen laut MEDLINE: Prodrugs. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsHumansRatsAnimalsDepressionIntestinesBiological AvailabilityHydrolysisEsters

Substanzen

ProdrugsEsters

Autor:innen und Institutionen

  • Drug Metabolism and Pharmacokinetics, Drug Safety and Pharmacokinetics Laboratories, Research Headquarters, Taisho Pharmaceutical Co., Ltd., Saitama, Japan s-inatani@taisho.co.jp.
  • Drug Metabolism and Pharmacokinetics, Drug Safety and Pharmacokinetics Laboratories, Research Headquarters, Taisho Pharmaceutical Co., Ltd., Saitama, Japan.

ORCID-Profile: Shoko Inatani, Kohnosuke Kinoshita

Zitieren

APA

Inatani, S., Ochi, M., Kinoshita, K., Yamaguchi, J. I., & Endo, H. (2023). Preclinical Metabolism and Disposition of TP0473292, a Novel Oral Prodrug of the Potent Metabotropic Glutamate 2/3 Receptor Antagonist TP0178894 for the Treatment of Depression. Drug Metabolism and Disposition. https://doi.org/10.1124/dmd.122.001116

Vancouver

Inatani S, Ochi M, Kinoshita K, Yamaguchi JI, Endo H. Preclinical Metabolism and Disposition of TP0473292, a Novel Oral Prodrug of the Potent Metabotropic Glutamate 2/3 Receptor Antagonist TP0178894 for the Treatment of Depression. Drug Metabolism and Disposition. 2023. doi:10.1124/dmd.122.001116

BibTeX
@article{Inatani2023,
  author = {Inatani, Shoko and Ochi, Motoki and Kinoshita, Kohnosuke and Yamaguchi, Jun-Ichi and Endo, Hiromi},
  title = {Preclinical Metabolism and Disposition of TP0473292, a Novel Oral Prodrug of the Potent Metabotropic Glutamate 2/3 Receptor Antagonist TP0178894 for the Treatment of Depression},
  journal = {Drug Metabolism and Disposition},
  year = {2023},
  doi = {10.1124/dmd.122.001116}
}
Kostenlos starten →